News Releases

News Category

Year

22 Dec '2020

Advaxis Announces Listing Transfer to Nasdaq Capital Market and Additional 180-day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

PRINCETON, N.J. , Dec. 22, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it received a positive determination from the Nasdaq Stock Market granting

PDF Version

27 Nov '2020

Advaxis, Inc. Announces Closing of $9.2 Million Public Offering

PRINCETON, N.J. , Nov. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the closing of an underwritten public offering of 26,666,666 shares of

PDF Version

24 Nov '2020

Advaxis, Inc. Announces Pricing of $8 Million Public Offering

PRINCETON, N.J. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of (i) 26,666,666

PDF Version

23 Nov '2020

Advaxis, Inc. Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

PRINCETON, N.J. , Nov. 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it intends to offer and sell shares of its common stock and

PDF Version

09 Nov '2020

Advaxis Presents Updated Data from Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Disease control rate of 67% and overall response rate of 17% in first six evaluable patients with immediate prior progression on KEYTRUDA ® Biomarker data confirms on-mechanism activation of innate and adaptive immune responses to ADXS-503 ADXS-503 appeared safe and well tolerated as a

PDF Version

26 Oct '2020

Advaxis’ ADXS-503 (HOT Lung) Demonstrates Pronounced and Sustained Tumor Control in Ongoing Phase 1/2 Lung Cancer Trial

Disease control rate of 67% in first six evaluable patients who had progressed on KEYTRUDA Approximate 50% improvement in disease control rate versus the rate s reported in other checkpoint rechallenge studies Durable, sustained tumor control of over 43 and 33 weeks observed in first two

PDF Version

15 Oct '2020

Advaxis to Present Data from Ongoing ADXS-503 Phase 1/2 Clinical Trial at SITC 2020

PRINCETON, N.J. , Oct. 15, 2020 (GLOBE NEWSWIRE) -- Advaxis , Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it will present an ePoster at the 35 th Annual Meeting of the Society for Immunology

PDF Version

29 Sep '2020

Advaxis, Inc. Adopts Limited Duration Stockholder Rights Plan

PRINCETON, N.J. , Sept. 29, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that its Board of Directors has approved the adoption of a limited duration

PDF Version

24 Sep '2020

Advaxis Announces FDA Clearance of New IND for ADXS-504 for Treatment of Prostate Cancer

Strategic transition to Investigator sponsored IND from previously announced Advaxis sponsored IND Initiation of investigator sponsored Phase 1 study of ADXS-504 in prostate cancer on-track for Q4 2020 PRINCETON, N.J. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc.

PDF Version

10 Sep '2020

Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update

Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors Enrolling in Phase 1/2 Study efficacy expansion of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two of three evaluable patients

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 26